|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smyth EC, Lagergren J, Fitzgerald RC,
Lordick F, Shah MA, Lagergren P and Cunningham D: Oesophageal
cancer. Nat Rev Dis Primers. 3:170482017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Napier KJ, Scheerer M and Misra S:
Esophageal cancer: A Review of epidemiology, pathogenesis, staging
workup and treatment modalities. World J Gastroint Oncol.
6:112–120. 2014. View Article : Google Scholar
|
|
4
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Morgan MA, Lewis WG, Crosby TD, Escofet X,
Roberts SA, Brewster AE, Harvard TJ and Clark GW: Prospective
cohort comparison of neoadjuvant chemoradiotherapy versus
chemotherapy in patients with oesophageal cancer. Br J Surg.
94:1509–1514. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tepper J, Krasna MJ, Niedzwiecki D, Hollis
D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D and Mayer
R: Phase III trial of trimodality therapy with cisplatin,
fluorouracil, radiotherapy, and surgery compared with surgery alone
for esophageal cancer: CALGB 9781. J Clin Oncol. 26:1086–1092.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
van Hagen P, Hulshof MC, van Lanschot JJ,
Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ,
Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative
chemoradiotherapy for esophageal or junctional cancer. N Engl J
Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Developmental Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tam W: Identification and characterization
of human BIC, a gene on chromosome 21 that encodes a noncoding RNA.
Gene. 274:157–167. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Eis PS, Tam W, Sun L, Chadburn A, Li Z,
Gomez MF, Lund E and Dahlberg JE: Accumulation of miR-155 and BIC
RNA in human B cell lymphomas. Proc Natl Acad Sci USA.
102:3627–3632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zang YS, Zhong YF, Fang Z, Li B and An J:
miR-155 inhibits the sensitivity of lung cancer cells to cisplatin
via negative regulation of Apaf-1 expression. Cancer Gene Ther.
19:773–778. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Johansson J, Berg T, Kurzejamska E, Pang
MF, Tabor V, Jansson M, Roswall P, Pietras K, Sund M, Religa P and
Fuxe J: miR-155-mediated loss of C/EBPbeta shifts the TGF-β
response from growth inhibition to epithelial-mesenchymal
transition, invasion and metastasis in breast cancer. Oncogene.
32:5614–5624. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gironella M, Seux M, Xie MJ, Cano C,
Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, et
al: Tumor protein 53-induced nuclear protein 1 expression is
repressed by miR-155, and its restoration inhibits pancreatic tumor
development. Proc Natl Acad Sci USA. 104:16170–16175. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao H, Huang S, Liu A and Chen Z:
Up-regulated expression of miR-155 in human colonic cancer. J
Cancer Res Ther. 14:604–607. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu R, Liao J, Yang M, Shi Y, Peng Y, Wang
Y, Pan E, Guo W, Pu Y and Yin L: Circulating miR-155 expression in
plasma: A potential biomarker for early diagnosis of esophageal
cancer in humans. J Toxicol Environ Health A. 75:1154–1162. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang J, Cheng C, Yuan X, He JT, Pan QH
and Sun FY: microRNA-155 acts as an oncogene by targeting the tumor
protein 53-induced nuclear protein 1 in esophageal squamous cell
carcinoma. Int J Clin Exp Pathol. 7:602–610. 2014.PubMed/NCBI
|
|
17
|
Zhang W, Ji W and Zhao X: miR-155 promotes
anaplastic thyroid cancer progression by directly targeting SOCS1.
BMC Cancer. 19:10932019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li DP, Fan J, Wu YJ, Xie YF, Zha JM and
Zhou XM: miR-155 up-regulated by TGF-β promotes
epithelial-mesenchymal transition, invasion and metastasis of human
hepatocellular carcinoma cells in vitro. Am J Transl Res.
9:2956–2965. 2017.PubMed/NCBI
|
|
19
|
Zhang J, Ye Y, Chang DW, Lin SH, Huang M,
Tannir NM, Matin S, Karam JA, Wood CG, Chen ZN and Wu X: Global and
Targeted miRNA expression profiling in clear cell renal cell
carcinoma tissues potentially links miR-155-5p and miR-210-3p to
both tumorigenesis and recurrence. Am J Pathol. 188:2487–2496.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shao C, Yang F, Qin Z, Jing X, Shu Y and
Shen H: The value of miR-155 as a biomarker for the diagnosis and
prognosis of lung cancer: A systematic review with meta-analysis.
BMC Cancer. 19:11032019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gao S, Zhao ZY, Zhang ZY, Zhang Y and Wu
R: Prognostic value of MicroRNAs in esophageal carcinoma: A
meta-analysis. Clin Transl Gastroenterol. 9:2032018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pouliot LM, Chen YC, Bai J, Guha R, Martin
SE, Gottesman MM and Hall MD: Cisplatin sensitivity mediated by
WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer
Res. 72:5945–5955. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gasparini P, Lovat F, Fassan M, Casadei L,
Cascione L, Jacob NK, Carasi S, Palmieri D, Costinean S, Shapiro
CL, et al: Protective role of miR-155 in breast cancer through
RAD51 targeting impairs homologous recombination after irradiation.
Proc Natl Acad Sci USA. 111:4536–4541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao K, X, Chen X, Zhu Q, Yin F, Ruan Q,
Xia J and Niu Z: Inhibition of miR-140-3p or miR-155-5p by
antagomir treatment sensitize chordoma cells to chemotherapy drug
treatment by increasing PTEN expression. Eur J Pharmacol.
854:298–306. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Babar IA, Czochor J, Steinmetz A, Weidhaas
JB, Glazer PM and Slack FJ: Inhibition of hypoxia-induced miR-155
radiosensitizes hypoxic lung cancer cells. Cancer Biol Ther.
12:908–914. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Meng F, Qian L, Lv L, Ding B, Zhou G,
Cheng X, Niu S and Liang Y: miR-193a-3p regulation of
chemoradiation resistance in oesophageal cancer cells via the PSEN1
gene. Gene. 579:139–145. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lv L, Deng H, Li Y, Zhang C, Liu X, Liu Q,
Zhang D, Wang L, Pu Y, Zhang H, et al: The DNA
methylation-regulated miR-193a-3p dictates the
multi-chemoresistance of bladder cancer via repression of
SRSF2/PLAU/HIC2 expression. Cell Death Dis. 5:e14022014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tang F, Hajkova P, Barton SC, O'Carroll D,
Lee C, Lao K and Surani MA: 220-plex microRNA expression profile of
a single cell. Nat Protoc. 1:1154–1159. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang JX, Chen ZH, Xu Y, Chen JW, Weng HW,
Yun M, Zheng ZS, Chen C, Wu BL, Li EM, et al: Downregulation of
MicroRNA-644a promotes esophageal squamous cell carcinoma
aggressiveness and stem cell-like phenotype via dysregulation of
PITX2. Clin Cancer Res. 23:298–310. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ma K, He Y, Zhang H, Fei Q, Niu D, Wang D,
Ding X, Xu H, Chen X and Zhu J: DNA methylation-regulated
miR-193a-3p dictates resistance of hepatocellular carcinoma to
5-fluorouracil via repression of SRSF2 expression. J Biol Chem.
287:5639–5649. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lord CJ and Ashworth A: The DNA damage
response and cancer therapy. Nature. 481:287–294. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Powell SN and Bindra RS: Targeting the DNA
damage response for cancer therapy. DNA Repair (Amst). 8:1153–1165.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ivashkevich A, Redon CE, Nakamura AJ,
Martin RF and Martin OA: Use of the gamma-H2AX assay to monitor DNA
damage and repair in translational cancer research. Cancer Lett.
327:123–133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bouwman P and Jonkers J: The effects of
deregulated DNA damage signalling on cancer chemotherapy response
and resistance. Nat Rev Cancer. 12:587–598. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lujambio A, Ropero S, Ballestar E, Fraga
MF, Cerrato C, Setién F, Casado S, Suarez-Gauthier A,
Sanchez-Cespedes M, Git A, et al: Genetic unmasking of an
epigenetically silenced microRNA in human cancer cells. Cancer Res.
67:1424–1429. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nagata K, Puls A, Futter C, Aspenstrom P,
Schaefer E, Nakata T, Hirokawa N and Hall A: The MAP kinase kinase
kinase MLK2 co-localizes with activated JNK along microtubules and
associates with kinesin superfamily motor KIF3. EMBO J. 17:149–158.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nagy A, Lanczky A, Menyhart O and Gyorffy
B: Author Correction: Validation of miRNA prognostic power in
hepatocellular carcinoma using expression data of independent
datasets. Sci Rep. 8:115152018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li N, Cui T, Guo W, Wang D and Mao L:
miR-155-5p accelerates the metastasis of cervical cancer cell via
targeting TP53INP1. Onco Targets Ther. 12:3181–3196. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qu Y, Zhang H, Sun W, Han Y, Li S, Qu Y,
Ying G and Ba Y: MicroRNA-155 promotes gastric cancer growth and
invasion by negatively regulating transforming growth factor-β
receptor 2. Cancer Sci. 109:618–628. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ji H, Tian D, Zhang B, Zhang Y, Yan D and
Wu S: Overexpression of miR-155 in clear-cell renal cell carcinoma
and its oncogenic effect through targeting FOXO3a. Exp Ther Med.
13:2286–2292. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang C and Lees-Miller SP: Detection and
repair of ionizing radiation-induced DNA double strand breaks: New
developments in nonhomologous end joining. Int J Radiat Oncol Biol
Phys. 86:440–449. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chiu YC, Tsai MH, Chou WC, Liu YC, Kuo YY,
Hou HA, Lu TP, Lai LC, Chen Y, Tien HF and Chuang EY: Prognostic
significance of NPM1 mutation-modulated microRNA-mRNA regulation in
acute myeloid leukemia. Leukemia. 30:274–284. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kang Y, Park MA, Heo SW, Park SY, Kang KW,
Park PH and Kim JA: The radio-sensitizing effect of xanthohumol is
mediated by STAT3 and EGFR suppression in doxorubicin-resistant
MCF-7 human breast cancer cells. Biochim Biophys Acta.
1830:2638–2648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pienta KJ: Preclinical mechanisms of
action of docetaxel and docetaxel combinations in prostate cancer.
Semin Oncol. 28:3–7. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu Q, Zhang C, Ding X, Deng H, Zhang D,
Cui W, Xu H, Wang Y, Xu W, Lv L, et al: Preclinical optimization of
a broad-spectrum anti-bladder cancer tri-drug regimen via the
Feedback System Control (FSC) platform. Sci Rep. 5:114642015.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
An Y, Cai B, Chen J, Lv N, Yao J, Xue X,
Tu M, Tang D, Wei J, Jiang K, et al: MAP3K10 promotes the
proliferation and decreases the sensitivity of pancreatic cancer
cells to gemcitabine by upregulating Gli-1 and Gli-2. Cancer Lett.
329:228–235. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Su H, Hu N, Yang HH, Wang C, Takikita M,
Wang QH, Giffen C, Clifford R, Hewitt SM, Shou JZ, et al: Global
gene expression profiling and validation in esophageal squamous
cell carcinoma and its association with clinical phenotypes. Clin
Cancer Res. 17:2955–2966. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kim SM, Park YY, Park ES, Cho JY, Izzo JG,
Zhang D, Kim SB, Lee JH, Bhutani MS, Swisher SG, et al: Prognostic
biomarkers for esophageal adenocarcinoma identified by analysis of
tumor transcriptome. PLoS One. 5:e150742010. View Article : Google Scholar : PubMed/NCBI
|
